India - a biotech growth catalyst

India is among the top 12 destinations for biotechnology in the world, with approximately 3% share in the global Biotechnology industry. India is also the leader in the global supply of DPT, BCG and measles vaccines.

The Biotechnology industry in India comprises of 2700+ Biotech start-ups and it expects to grow up to 10,000 by the year 2024. There are more than 2500+ Biotech companies in India.

India has the highest number of US FDA approved plants (665) outside of the US, 2000 manufacturing plants compliant with WHO-GMP. Indian companies also were responsible for 33% of market authorizations granted by USA in FY 20.

  • By 2025, the Indian Biotechnology industry is expected to reach $150 bn
  • By 2025, the contribution of the Indian biotechnology industry in the global biotechnology market is expected to grow to 19% from 3% in 2017

100% FDI is allowed under the automatic route for greenfield pharma.

100% FDI is allowed under the government route for brownfield pharma in upto 74% FDI is under automatic route and beyond 74% is under the government approval route.

FDI up to 100% is allowed under the automatic route for the manufacturing of medical devices.

For further details, please refer FDI Policy

  • %

    Bio-services revenue share

  • %

    Bio-pharma revenue share

  • %

    Bio-agri revenue share

  • %

    Expected CAGR (2016-22)


World's largest producer of recombinant Hepatitis B vaccine

BT Cotton

World's largest producer of BT Cotton


World's highest number of USFDA approved plants

Biotechnology Information Kit
Biotechnology Information Kit

Industry Scenario

The Indian Biotechnology industry that was valued at $62 bn in 2019 will reach $150 bn target by 2025.

The sector is divided into five major segments- Bio-pharma, Bio-services, Bio-agri, Bio-industrial, and Bio-informatics. The biopharmaceutical sector accounts for the largest share of the biotech industry with a share of 64% of total revenues, followed by bio-agri with 14% market share (2019), bio-services accounted for 18% of the Biotech industry. India is becoming a leading destination for clinical trials, contract research, and manufacturing activities, which is further fuelling the growth of the bio-services sector, while the remaining market is catered by bio-industrial (6%).

According to UNESCO, the expenditure on research and development (as a percent of GDP) has been 0.8% for India  and the target set by the Economic Advisory Council to the Prime Minister (EAC-PM) for the year 2022 is 2%.

  • India currently has 5,48,719 sq. ft. of incubation space
  • 50 bio-incubators have been supported by BIRAC and established since 2014, with more planned across the country

India is one of the first countries to have a department dedicated to Biotechnology. The Department of Biotechnology has also set up BIRAC (Biotechnology Industry Research Assistance Council). This not-for-profit an interface agency to strengthen and empower emerging biotechnology enterprises to undertake strategic research and innovation.


  • Growing population

    India to become the world’s most populous country by 2030

  • Rising demand for treatments

    Increased insurance penetration and a growing burden of disease

  • Medical infrastructure facilities

    $200 bn expenditure planned on medical infrastructure over the next decade

  • Strong skilled manpower pool

    ‘National Biopharma Mission’, an Industry-Academia mission to skill the workforce

  • Cost competitive manufacturing

    Development of life-science clusters builds collaborations between research institutes and the private sector

Industrial Information System (IIS) Portal

GIS - based map displaying available infrastructure for setting up manufacturing operations in the state.

Major Investors

Data On Map

Biotechnology industry in India

Latest In Biotechnology

RegulationsNov 19, 2020

Standard Operating Procedure (SOP) for Processing FDI Proposals

Read Now


Standard Operating Procedure (SOP) for…


Guidelines for Evaluation of Nano Based Agri…

Press Release

Declaration of the private sector on Climate…

FDI Policy 2020

DPIIT released the 'Consolidated FDI Policy'…


Customs (Administration of Rules of Origin…


Asked Questions

Does BIRAC offer any capacity building support for researchers, innovators, entrepreneurs?

Yes, BIRAC conducts roadshows and Intellectual Property workshops to sensitize the target audiences about the BIRAC support for the entrepreneurs and relevance of intellectual property. It also provides a platform for the aspiring entrepreneurs to gain knowledge about effective grant writing skills from the experts in the domain.

Was it helpful?

Does the Department offer any support to researchers in this sector? If yes, then at which stage of the research are they supported in?

Yes, the Department does offer support to researchers across all the stages of R&D - Ideation/ very early stage (SITARE, E-yuva), ideation to early stage (Biotechnology Ignition Grant Scheme (BIG)), ideation to late stage (Small Business Innovation Research Initiative (SBIRI)), (Biotechnology Industry Partnership Programme (BIPP)), translation (Promoting Academic Research Conversion to Enterprise (PACE)) and for social innovation (Social Innovation programme for Products: Affordable & Relevant to Societal Health) etc. This support is usually through awards, grants for research, provision of enabling platform for different stakeholders to collaborate and innovate. Usually, a researcher submits his/her proposal to Biotechnology Industry Assistance Council (BIRAC) based on which the support is provided.

Was it helpful?

Does BIRAC also support in any exchange programs of researchers with other countries?

Yes, BIRAC and Centre of Entrepreneurial Learning (CEL) of Judge Business School, University of Cambridge have initiated a partnership that enables five BIRAC supported applicants to take part in CfEL’s flagship intensive entrepreneurial boot-camp programme called “IGNITE”, which is aimed at providing academics (PhDs, post-docs and scientists) entrepreneurial opportunities to explore their innovative ideas and transform them into a business project. CfEL provides one week intense mentorship and training to the BIRAC supported candidates and for second week encourage them to interact and learn from the Cambridge’s entrepreneurial cluster.

Was it helpful?

What is Grand Challenges India (GCI)?

Grand Challenges is a family of initiatives fostering innovation to solve key global health and development. In 2012, the Bill & Melinda Gates Foundation (BMGF) and the Department of Biotechnology (DBT) signed an umbrella Memorandum of Understanding (MOU) to collaborate on mission-directed research and build Grand Challenges India to support health research and innovation which is the GCI. Under the GCI, proposals are called under various relevant topics on innovative solutions to help expand the pipeline of ideas to develop new preventions, therapies and interventions in this sector.

Was it helpful?

Does BIRAC offer any support to start-ups?

The Bioincubators Nurturing Entrepreneurship for Scaling Technologies (BioNest) allows harnessing of the entrepreneurial potential of start-ups by providing access to infrastructure as well as mentoring and networking platforms that the start-ups could use during their fledgling days. So far BIRAC has supported twenty bioincubation centers across India on similar lines.

For relevant guidelines, access the link.

Was it helpful?


Invest India Timeline


Disclaimer: All views and opinions that may be expressed in the posts on this page as well as post emanating from this page are solely of the individual in his/her personal capacity